CIBC analyst John Zamparo upgrades HEXO (TSX:HEXO) from Underperformer to Neutral.
ESSA Collaborator Janssen Suspends Enrollment In Phase 1 Study Of EPI-7386 With Apalutamide Or Abiraterone Acetate Plus Prednisone
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that